%0 Systematic Review
%T Impact of tofogliflozin on hepatic outcomes: a systematic review.
%A Pathak M
%A Parveen R
%A Khan P
%A Saha N
%A Agarwal N
%J Eur J Clin Pharmacol
%V 79
%N 10
%D 2023 Oct 18
%M 37462748
%F 3.064
%R 10.1007/s00228-023-03537-w
%X <B>OBJECTIVE: </B>Studies have demonstrated a high prevalence of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus (T2DM) patients. The aim was to review the effect of tofogliflozin on hepatic outcomes in T2DM patients.<BR><B>METHODS: </B>A literature search in PubMed, Science Direct and Cochrane Central Register of Controlled Trials was conducted for randomised clinical trials of tofogliflozin by applying predetermined inclusion and exclusion criteria.<BR><B>RESULTS: </B>A total number of four randomised clinical trials, including 226 subjects, were included in the review. There was a significant decrease in aspartate aminotransferase (AST) and alanine transaminase (ALT) levels in the tofogliflozin group as compared to the control or active comparator groups. Additionally, gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP) and magnetic resonance imaging proton density fat fraction (MRI-PDFF) levels were also significantly decreased in the tofogliflozin group. However, no significant difference was observed in levels of adiponectin.<BR><B>CONCLUSIONS: </B>Overall, an improvement in levels of hepatic parameters was observed in T2DM patients with concurrent liver disorders. However, a large number of clinical trials are needed to prove the efficacy of tofogliflozin on hepatic outcomes in patients with T2DM.